Annual Report 2019

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2019 89 The United Laboratories International Holdings Limited Annual Report 2019 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information (Continued) (a) Segment revenue and results: (Continued) Year ended 31 December 2018 Intermediate Bulk Finished Segment products medicine products total Elimination Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 REVENUE External sales 1,233,625 3,389,710 2,887,251 7,510,586 – 7,510,586 Inter-segment sales 1,617,804 423,009 – 2,040,813 (2,040,813) – Segment revenue 2,851,429 3,812,719 2,887,251 9,551,399 (2,040,813) 7,510,586 RESULT Segment profit 287,120 105,193 615,374 1,007,687 Unallocated other income 107,539 Unallocated corporate expenses (84,858) Other gains and losses, net (121,133) Gain on fair value change of embedded derivative components of convertible bonds 226,414 Loss on fair value change on investment properties (94,873) Finance costs (246,897) Profit before taxation 793,879